<SEC-DOCUMENT>0001354488-12-001236.txt : 20120320
<SEC-HEADER>0001354488-12-001236.hdr.sgml : 20120320
<ACCEPTANCE-DATETIME>20120320093454
ACCESSION NUMBER:		0001354488-12-001236
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120320
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120320
DATE AS OF CHANGE:		20120320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AEMETIS, INC
		CENTRAL INDEX KEY:			0000738214
		STANDARD INDUSTRIAL CLASSIFICATION:	INDUSTRIAL ORGANIC CHEMICALS [2860]
		IRS NUMBER:				261407544
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51354
		FILM NUMBER:		12702310

	BUSINESS ADDRESS:	
		STREET 1:		20400 STEVENS CREEK BLVD
		STREET 2:		SUITE 700
		CITY:			CUPERTINO
		STATE:			CA
		ZIP:			95014
		BUSINESS PHONE:		408-517-3304

	MAIL ADDRESS:	
		STREET 1:		20400 STEVENS CREEK BLVD
		STREET 2:		SUITE 700
		CITY:			CUPERTINO
		STATE:			CA
		ZIP:			95014

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AE BIOFUELS, INC.
		DATE OF NAME CHANGE:	20110714

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AE Biofuels, Inc.
		DATE OF NAME CHANGE:	20071212

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MARWICH II LTD
		DATE OF NAME CHANGE:	19840123
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>amtx_8k.htm
<TEXT>
<html>
<head>
    <title>amtx_8k.htm</title>
    <!--Licensed to: Issuer Direct Corp-->
    <!--Document Created using EDGARizerAgent 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
<hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">WASHINGTON, D.C. 20549</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">FORM 8-K</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CURRENT REPORT</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Date of Report (Date of earliest event reported): March 20, 2012</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 18pt; FONT-WEIGHT: bold">AEMETIS, INC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Exact name of registrant as specified in its charter)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">______________</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="80%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">Nevada</font></div>
</td>
<td valign="bottom" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">000-51354</font></div>
</td>
<td valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">26-1407544</font></div>
</td>
</tr><tr>
<td valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(State or Other Jurisdiction</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">of Incorporation)</font></div>
</td>
<td valign="bottom" width="25%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Commission</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">File Number)</font></div>
</td>
<td valign="bottom" width="26%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(I.R.S. Employer</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Identification No.)</font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">20400 Stevens Creek Blvd., Suite 700</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Cupertino, California 95014</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Address of Principal Executive Office) (Zip Code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">(408) 213-0940</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Registrant&#8217;s telephone number, including area code)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">N/A</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Former name or former address, if changed since last report)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">o</font> Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">o</font> Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">o</font> Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline;" face="Wingdings">o</font> Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 1pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman, serif; FONT-SIZE: 1pt">&#160;</font></div>

<div>
<hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="1">
<hr style="MARGIN-TOP: -13px; COLOR: #000000" noshade size="4">
<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<div>
<hr style="COLOR: black" noshade size="2">
</div>
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>
</div>

<div>&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item&#160;7.01 Regulation FD Disclosure.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">On March 20, 2012, the Company posted to its web site a press release announcing that Universal Biofuels Pvt. Ltd. (UBL), a subsidiary of Aemetis, has received a&#160;five-year Pharmacopoeia license to expand its current refined glycerin production to manufacture pharmaceutical grade glycerin at its Kakinada, India facility. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report and is incorporated herein by reference. The information contained herein and the attached exhibit are furnished under this Item 7.01 of this Current Report and are furnished to, but for purposes of Section 18 of the Securities Exchange Act of 1934 shall not be deemed filed with, the Securities and Exchange Commission. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated therein.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Item 9.01 Financial Statements and Exhibits</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(d) Exhibits</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a name="jump_exp_1"><!--efplaceholder--></a>Exhibit Number</font></div>
</td>
<td align="left" valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Description</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="11%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><a href="amtx_ex991.htm">99.1</a></font></div>
</td>
<td align="left" valign="top" width="89%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Press Release, dated March 20, 2012</font></div>
</td>
</tr></table>
</div>

<br>
<div id="PGBRK" style="TEXT-INDENT: 0pt; WIDTH: 100%; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">2</font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="2">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<br>
<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">SIGNATURES</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="middle" width="37%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="27%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="37%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="3" valign="middle" width="30%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Aemetis, Inc.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>
</td>
<td valign="middle" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="middle" width="37%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Date:&#160;&#160;March 20, 2012</font></div>
</td>
<td align="left" valign="top" width="3%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:</font></div>
</td>
<td align="left" colspan="2" valign="middle" width="27%" style="BORDER-BOTTOM: black 2px solid">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">/s/Eric A. McAfee</font></div>
</td>
<td valign="middle" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="middle" width="37%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="27%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Eric McAfee</font></div>
</td>
<td valign="middle" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="middle" width="37%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="middle" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" colspan="2" valign="middle" width="27%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Executive Officer</font></div>
</td>
<td valign="middle" width="11%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">3</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>amtx_ex991.htm
<TEXT>
<html>
<head>
    <title>amtx_ex991.htm</title>
    <!--Licensed to: Issuer Direct Corp-->
    <!--Document Created using EDGARizerAgent 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="TEXT-ALIGN: right"><font style="FONT-WEIGHT: bold">Exhibit 99.1</font></div>

<div style="TEXT-ALIGN: center"><img src="amtx_ex991.jpg" alt=""></div>

<div>&#160;</div>

<div>
<div align="center">
<table cellpadding="2" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="14%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline">&#160;</font></td>
<td align="left" colspan="3" valign="top" width="84%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold; TEXT-DECORATION: underline"><font style="DISPLAY: inline">For Immediate Release</font></font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="14%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Media Contact:</font></div>
</td>
<td align="left" valign="top" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Investor Relations</font></div>
</td>
<td align="left" valign="top" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Investor &amp; Analyst Contact:</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="14%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Andy Foster</font></div>
</td>
<td align="left" valign="top" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Michael Bayes</font></div>
</td>
<td align="left" valign="top" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Todd Waltz</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="14%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(408) 213-0928</font></div>
</td>
<td align="left" valign="top" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Liviakis Financial</font></div>
</td>
<td align="left" valign="top" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(408) 213-0925</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="14%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;</font></td>
<td align="left" valign="top" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">afoster@aemetis.com</font></font></div>
</td>
<td align="left" valign="top" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(415) 389-4670</font></div>
</td>
<td align="left" valign="top" width="28%">
<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline">twaltz@aemetis.com</font></font></div>
</td>
</tr></table>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Aemetis Announces Approval to Sell Pharmaceutical Grade Glycerin in India</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Aemetis subsidiary licensed for production and sale of pharmaceutical grade glycerin</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">CUPERTINO, Calif. &#8211; March 19, 2012 &#8211; Aemetis, Inc. (OTCPK: AMTX), an industrial biotechnology company producing renewable chemicals and advanced fuels, announced today that Universal Biofuels Pvt. Ltd. (UBPL), a subsidiary of Aemetis, has received a five-year Pharmacopoeia license to expand its current refined glycerin production to manufacture pharmaceutical grade glycerin at its approximately 15,000 metric tons per year processing facility in Kakanada, India.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Currently, UBPL is selling its refined glycerin into domestic industrial chemical markets at the U.S. dollar equivalent of approximately $800 per metric ton.&#160;&#160;The five-year license to manufacture pharmaceutical grade glycerin enables UBPL to expand into additional Indian industrial markets, including the large generic and branded pharmaceutical and personal care industries.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;With the ability to manufacture, sell and distribute pharmaceutical-grade glycerin, we are increasingly well positioned to provide glycerin, natural oils, and renewable fuels to a diverse range of industries and sectors with our products,&#8221; said Sanjeev Gupta, chairman and managing director of Universal Biofuels.&#160;&#160;&#8220;By investing in additional technology at our facility, our bio-refinery can quickly adapt to changing customer requirements and address both well-established and emerging markets.&#8221;</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">About Aemetis</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Headquartered in Cupertino, California, Aemetis is an industrial biotechnology company producing renewable chemicals and advanced fuels.&#160;&#160;Aemetis operates a 55 million gallon biofuels plant in California, and built and operates a nameplate 50 million gallon per year renewable chemicals and advanced fuels production facility on the east coast of India.&#160;&#160;In 2011, Aemetis received a California Energy Commission grant to commercialize technology that enables the production of advanced biofuels from both non-food and traditional feedstocks. For additional information about Aemetis, please visit <font style="DISPLAY: inline; TEXT-DECORATION: underline">www.aemetis.com</font>.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><font style="DISPLAY: inline; TEXT-DECORATION: underline">Forward Looking Statements</font></font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The information contained herein includes forward-looking statements related to future events.&#160;&#160;Statements regarding future events are based on current expectations and are necessarily subject to associated risks related to, among other things, the ability of the company to successfully commercialize its technologies, and the ability of the company to successfully penetrate existing glycerin markets as a new entrant. Actual results may differ materially from those in the projections or other forward-looking statements made herein. For information regarding other related risks, please see the "Risk Factors" section of the company&#8217;s filings with the SEC.</font></div>

<div style="TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>amtx_ex991.jpg
<TEXT>
begin 644 amtx_ex991.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`#9`34#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBJ][>0Z?9R75PQ6*,9)`R?0#\Z-A-I*[)R
M0JEF(`'))[5RNN>,H[-TBTUH+E\GS&.2J^F,8S^![5A7NOZKXBN/L%HNR.1F
M"QQ\%E_VCGT_"M[2O!-G!#NU'_2)C_"K$(OICH3^/Y5SNI*II3^\\N6*K8F\
M,*K+^9_H<RVM>(=6D/DS73;>=MJI&T?\!Y_.D&A>(;_+/;7+G_IL^#_X\:]+
MM[:WM(_+MH(X4S]U%"C/X5*Q"J6)P`,DFE["^LI"65N?\:HV_P"O4\O_`.$<
M\06F)$M9E*\@Q2`D?D<TG]L>(M+.);B\B+]!<*6S]-X->I4R6&*>,QS1)(AZ
MJZ@C]:/J]OA8/*E'^%4:?]=K')Z%XS%S*8-4:&$X&R49`8^_8>N>!77(ZNH9
M&#*>A!R*YG5O!EE=QM)8@6UQU`R?+8^X[?A^5<Y:WFK^$KR.&Y1A!)AFA+!E
M89P2"#P?_K9IJ<Z>D]5W''$U\+:.)5X_S+]?Z^\]*HJKI]_;ZG9)=6S%HW['
M@J>X(]:M5T)WU1ZD9*236S"BBB@84444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`-=TCC:21E5%!+,QP`!W-<!X
M@U>ZUW4_[*TYM]N6"@(>)6'4D_W1^7&:VO&VI"UTM;2*8K-<'YE4\^7WS[$X
M'OS[U!X(TGR;5]1FC`DE^6(GJ$[G\3_+WKGJ-SE[-?,\O%3E7K+"P>F\G^AJ
M:/X<LM&5)@ADNMH5I#S@GKM]!S^7XUM4UT61&1AE6&"/:JVGS/)`8YB?/B.U
MP>OL?RJN:,)JGWV^7]?@STZ5&-.G:"LD/\W;J!B;.'C!7TR"<_CR*=><64Y_
MZ9M_*J>I3+;WME*WW06!/H#@59U"01Z?.QSRA7CWX_K7,ZRY:T6_AO\`<U?_
M`#^XZ.36#77_`#L/M6+6<#,<DQJ2?PJ,3,^J-$I_=QQ?-_O$C^G]:73W$FGP
M,.@0+^7']*K:6QFGO+C=N5Y-JG'8=/T(H]JVJ,4_BU^25_SL'+;G;Z?YFE65
MJVDV>O63*=ID4'RIE_A/U[CU']:M7\C+"L,3$33-L3';U/TQ5I$5%"HH51T`
M&!73SJ<W#HM_G_7XHPJ4HSIVFKIGFVGZA?>%=7^R798VZMB2,'*D'^)?\^U>
MCPS1W$"31,&CD4,K#N#6%XLTE;_29)HH5:ZA`8,%^8J,Y&?Q)Q5/P+J(FT^6
MQ>0F6%MR*<?</IWX.?S%3"\)\CVZ'EX=RPU?ZO)WB]8_Y'64445T'J!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M139)%BB>1SA$4LQ]`*`//;W_`(GWCL6S_P"I27RMK<?*F2PX]2&_.N[8)86:
M^4A\J%`HC7G"C`_05Q7@>%[K6+N^E(=D3EFY.]SU_(-^==]7-2BY1<EHV>=E
M:3C*M):R;?R&HZR(&1@RGH0<BLC4I)+"_2XB.%E&'7/WL?\`UL4ZZ@DTPFZM
M#^[)_>1L?E&>F!4LOD:Q9,8L^8F2%X!!QP#[&N#%595H.C\-6.J\_-=]+H]R
MG%0:GO%Z/_@D.L2)/IL$R8(9Q@]QP>*S=8U8VO@RXG9F,H)C#,<_-U'7KVI$
MN0=/DMI.<$/&>>#GD?EFN,\9ZBXMX--5OD9O/<<]LJO\V_(5Y4<7[;$<R^W&
MS_KY?<SU<#@O:U8TWLI7^6YW>@ZBT_@>VO"3YC1LI/0[MQ4GCWYK1T5?*TTN
MY`5F+9/8=/Z5Y7X0U>>*X?3'E<P3#**6)"LN3P.P.2?J!7>/>R?8HK:-BJ*#
MNQQDDGCZ8-;SQL*%=2DM(0LEYW_R_(,PR^5*K*FMI._R_P"!L:6GN;[4YKIO
MNQC"`]L]/TS^=:LLJPQ-(YPJC)K-MI(=+TN.1P/,D&[`ZMZ?IBF69FU602W(
M7R(SPB]&;W'?_/O7;AL1[*$:7Q59ZOROW[61Y=2'-)SVBM/^&-2"0RQ"0C`8
M94>@[9]Z\ZN9W\+>+KB2&/=%R1'C8&1AG`]@?_0:])KA/'\"K=V5P"=[HR$=
ML*01_P"A&O1K1:@G?5'@YJG[)58:.+O^AW0(90RD$'D$=Z6LOP[<?:O#UC)@
MC$03G_9^7/Z5J5NG=7.^G-3@I+J%%%%,L****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`JEK/_(#U#_KVD_\`035VJ6L_\@/4
M/^O:3_T$TI;,SJ_PY>C.>\!0XTJ[F7`=YMF3[*"/_0JZ*6^^RX^TQ,%)P)$Y
M4_U'T_G6#X"8'1KA.XN"3^*K_A74LH92K`$$8(/>N>,9.DN1V?X&.7.*PT+K
M2Q62[M+Q6B256W`@KR"16#,D^E7K"-L9'RMP<KG_`.M6AJ&D;@'M(U!R2RYZ
M_3MZUBNTF!&Y;"9`4G[OKQVKYS-:]56C6A::VDGH_P"O4][#0@[N#NGNF)-+
MYDCRM@;B6/H*\YO)SK^OIY895E944'&5'?\`J:ZSQ/<_9]#E`9E:4B-2/?D_
MH#6%X-MO,U">X(0B*/:,]06/4?@"/QKCPON4YXB6_P#7ZGTF`BJ-">(ZK1&7
M.AT;7V`'$$P903G*]1^E>CQNDL:R(P9&`8$=P:Y;QE9?NH+N.)!ABLKA>3D#
M;G\B*U/#-S]IT.$%BSQ$QMD=,=!^1%3BG[6A"MU6C_K^MPQK]OAH5^JT?]?U
MN=)#'+JFH9<]>7(XPOM6^TUII\2QLXC4=%Y)_P`:Y9&DP8T+8<@%0?O>G%:^
MGZ0ZR^9=QKM'1"<\^O'&*[LKQ%7548<TY;R>R_KUU/F\3".G/*R70OQ7XN2P
MMH7<`XWM\J_GU_2N?\>1`Z1:RL<NLX7CIRIS_(5U:J%4*H``&`!VKE_'I']B
M0#/)N0<?\!:OHW&:IOG=W]R/"S%Q>&G9="WX.D#^&;=1U1G4_P#?1/\`6MZN
M?\&1E/#<+'^-W8?GC^E=!6U/X$/"?[O#T7Y!1115G0%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`5'<0K<VTL#_`')$*-]"
M,5)10#5]&<%X!N2M[>6NW.^,29STVG'_`+-^E=G</>*C&&.'CD98DD?3'6N&
MC;^P/';!CL@DD(.WY5V/R/P!(_[YKN[B^MK6R:]FF5;=5#&3J,'IC'7.17+3
M@YPY$VGMH>?E<^2DZ<MXMHQ'N]6",6$RKCD^5C'XXK+N;Q%(>ZN54G@&5\9_
M.M&ZU'Q#J,8CTK3&LU<@BZNG4$+_`+G)'Z_2L"?P->R13WNLZTH\I"[2!6FP
MH&3R<'I7'+(/:-.OB';L]7^>AZCS*:]VA1N_N7_!.3\4ZDE]?1Q1$&*`$9XY
M8GD@CM@"I-"UQ=-T_P`L6A=G<LS%\'TZ8]JJ^'])&O\`B*&RW2"!V+2.!R$'
M/X$\#ZFO3H_A_H:##+<2>[2_X`5M@L!@I1E"LFX+;=?-V:/<SW$XNAA:.$HM
M1G:\O\MGUO\`<NYPNH>(5O[":U>SP)%P#YO0]0>GJ!69X>UI=*N'282M!*`-
MJ`'#9X/)&!C/Z5Z>W@'0F!Q'.OTE/'YUY5XBTL:-KUY8*Q9(WRASSM(!'XX(
MS[TL?@,#3@HT(M1>^K_5L.&ZF)Q%.MA<3)-M77Z]%Y'HMK>*^7M;@$XY,;]/
MRK5CO=5<`IYC+ZB($?RKE-*\'WUQIMIJFCZNBO,@8_>CVGNN1G.#D?A726=[
MXETHO_;%K_:%O][S[7;N3VV8!;\O7K64,A5-WH8A\O;9_F>(\PJ*7)B*-I+1
M]4;T$EZT8:2*')Y^^RX_#!KDOB!,#)8P`_,`[L/K@#^1KL;2[@O[5+FVD$D3
M_=8`CO@\'D5Y]K@GU_Q;+:VPRT>84W<`;<EL_CNKLJ0E3AR-MOS/*S6IS4.6
M*UDTE;[SL_#5NUMX<L8V(),?F9'HQ+#^=:M,AA2W@CAC&(XU"*/0`8%/KIBK
M)([:4.2"AV5@HHHIEA1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`'&^.M+:2*/4XR3Y0$4@]%R<'\SC\15_PCJD6H:7
M%;NW^DVB[".GR=%(_#C\/>N@FACN()(95#1R*593W!KS:[2?PMXHWQ9CA+[U
M"'(:(G[O/TQSW&?0USS_`'<^?H]SR<0GA<0L0OAEH_\`/^OU/3*XSXC:U+IN
MCPVENY22\+H_R@@Q;<,.>A.Y?UKK;2[@OK9+BWD#Q.,@BO&_'FHC4/%=SLD6
M2*W"PH5'H,M_X\6I8FIRT].I]=D.&6)Q:;UC%7_R_P`S?^%NFN9[W5&!"!?L
MZ<CDDAF_+"_G7I=<]X(L?L'A*Q4J@>93,Q3^+<<@GWV[1^%=#5T(<M-(PS;$
M>WQDY=$[+Y:!7F?Q1TR475GJH(,)06S#^ZP+,/KD$_E[UZ96=KNFQZKHUU:O
M%$\AB?R3*.$DVD*WMC/6G6ASP:)RW%?5<3&KTV?HSEOAEJIN=(FTU\;K1MR=
M.48D_H<_F*[JO$_`NH?V?XMLRTA2.?,#X&=V[[H_[ZVU[/=7,-G;27$[A(HQ
MEF-9X6?-3UZ'7G^'5#%N726O^?XZ_,SM>OHM(T^:^QBX9?*B/7+'I[<8S^%8
M'@/3W!N-2?@,/*3WY!8_H/UK`N)+GQ/XB(B)8RN5B#G&R,9(SZ8'/Y]:]/M;
M:&SMH[>W0)%&,*HIQ;JSYNB/CZ$GC,1[7[,-O-]_Z\B6BBBN@]8****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"J6JZ9!JUB]M.HY!*/CE&[$5=HI-)JS)E%23C+9GE:OJ/A;5F"L05;#<'9*/
MQZ]:[_0]=@UNW=XT,4D9`>-F!Q[CU'O@5=O+&VU"W,%W"LL9.<'L?4'J#7$W
M_@>\@E\W39EE0'*JQVNOIST/UXKG49TG[NJ/*5'$8.5Z7O0[=4=]17F_]N^(
MM#G6"[9VQD[+@!MW_`NI_.M!/B"X7Y]-5F]5FQ_[*:I8B'70VCFE#:=XOLT=
MQ17$-\03M.W3`#V)GS_[+68WB;7]2F:.V=EW<>7!$#C/'7!(^N:;Q$.FH2S7
M#K2%Y/R7^=CN-:UF#1;,3RJ9&8[4C4@%CC^7OSUK@KC4=2\5ZC!9EE16;Y(Q
MG8IQR3W/?Z5HV7@O4;RX$^J3^6&.7&_?(WX]/QR?I796&E6.EJRV=LL6[[QR
M23^)YQ[5#C.H]=$8RIXG&/W_`'(=NK(='T6UT>U6.)%:7'SS%?F;U^@X'%:5
M%%="22LCU80C"*C%62"BBBF4%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`(0&!!Z'BLB7POHTS
M;I+/)_ZZO_C6Q12<4]T1.G":M-)^IC)X4T2-PZV6&'(/FO\`XUL(BHBHHPJC
M`'M2T4**6R"%*%/2"2]`HHHIEA1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`45R7C;Q%=:-':0V,JI/*2['`8A1QT([D]?]DU+X,\
M0W&N6L\=V`9[?;NDX&_<6[`<8``K;V$_9^UZ&'UFG[7V/4ZBBBBL3<**XG7?
M$/B;0/+>XM=.>&3A9(U<J#Z'+#![_P"352R\6^*=1A,UGI5K-&K;2R1M@'@X
M^_[BNE86;CS75O4Y)8RG&7(T[^AZ#17#_P!O>-/^@'!_WZ;_`.+K.NO'?B&Q
ME\J[TZV@D(W!9(74D>O+=.*(X6<M(M/YBECJ<5>2:^1Z31573;E[S2K.ZD"A
MYH$D8+T!*@G'YUSOB?7->T.<S6]I:RV!QMD*.Q3H#O((`R3Q64*3G+D6YO4K
M1A#G>QUE%><Z;\0M0GU.VANH+-8))%1V4,I4$XSDL1QUKT1'22-9(V5T8`JR
MG((/<&G5HSI.TB:&(A63<.@ZBBHYYH[:WDGE;;'&A=SZ`#)K(W)**\RD^)&J
M&5S%:V:QY.T,K$@=LG<,G\*[3P]=ZU>VS3ZM;06X;_5QHK*XP3G<"3CMBNBI
MAITXWD<M+%TZLN6%S9HJEJC:DEF6TI+9[@'.VXSAA@\#'?..O%>?-\1=91BK
M6MDK`X(,;@@_]]4J6'G55XCK8JG1:4STZBN'_M[QI_T`X/\`OTW_`,745QXG
M\7VD32SZ+"D:@EF\AR%`[G#<4UAI/1-?>2\9!:M/[F=[17!^'?&NI:OKMM8W
M$%HL4N[<8T8-PI/&6/I6IXP\1WGA_P"Q?9(X'\_?N\U2<;=N,8(]32>&J*HJ
M;W8XXNDZ3JK9'445YW9>,_$VHY^QZ7;S@'!9(7(!]SNP*+[QEXFTSR_MNFVL
M'F9V;XWYQC/\?N*OZI4ORW5_4CZ_2Y>:SMZ'HE%<#:^*/%M[;)<6VD6TL+YV
MNL;8.#@_Q^HJI=>._$-C+Y5WIUM!(1N"R0NI(]>6Z<4+"5&[)J_J#QU)+F:=
MO0])HK"\*:S<Z[I+W5TD22+,8P(@0,``]R?6LCQ!XB\2:#)OEM;!K5W*Q2*K
MGW`/S#!Q_(UFJ$G-T^IM+$0C3536S.THKAM$\2^)M?>46EMIBK%C>\JN`,]!
MPQ/8UW-34I.F[2W*HUHU5S1V"BL7Q!XEM/#\"F4&6X?[D"M@D>I]![USL>J^
M--7'G6-FEK;MRA95&1C(^_USD<@8JH4)2CS;+S)GB(0ER:M^1WE%>:7'BGQ5
MH=R$U*)#NSM$L0"MCT9<9ZCO78^&==;Q!ITERUN(6CD,9`?<#P#GIQUIU,-.
M$>9ZKR)I8JG4ER*Z?9HVJ***P.D****`"BBLGQ-=BR\-W\V6!\HHI7J"WRC]
M351CS245U)G)1BY/H<+XA5O$?B;41"1&FG6KYW=6\LG('_`CCZ5%\/KE8/$P
MB8$FXA>-<=B,-S^"FMSX<6S-9ZA>2$/YTHC.[DD@9.?KO%<87_L/Q,QB+;;.
M[('J55L>W45ZT;24Z"Z(\.7N.&)?5Z_UZ'ME%%%>.>\<?\1_^1>M_P#K[7_T
M!Z/AQ_R+UQ_U]M_Z`E'Q'_Y%ZW_Z^U_]`>CX<?\`(O7'_7VW_H"5W?\`,)\S
MS?\`F.^1V%<KX\TJ?4='AEM8&FG@ESM1=S%3P<`<GG;7550TO6;'68I)+&8R
M+&VULH5P?Q%<M*4H2YTMCMK0C4BZ<GN+HL;Q:%I\<B,CI;1JRL,$$*,@BHO$
M2A_#>I`_\^[G\AFM.LWQ!_R+FI?]>TG_`*":(N\T_,<E:FUY'CUS8M;V%E=\
MF.Y5N3T#*Q!'Y;3^->L>$KT7WABQ<;0T:>2P4YQMX&?<@`_C7$K`+KX8LXZV
MMWO^N2!_[/\`I6A\-K\A[S3F)P0)T&.!T5OYK^1KT<3^\I-_RL\C!VHUXKI*
M*/0:X[XAZBUKI5M:QO(CW$C9*G`*!<,#]=PXKL:\WUN"3Q'X^%I&BRP6OEI+
ML;&(PPWGZ@L1^%<>%BG4YI;+4]#&R:I<L=WH<=<VSVLJQN06,:2<>C*&'Z$5
M[S7C_C4`>+KX`8`\O`'_`%S6O8*WQLN:%.7?_@'+ET.2I4BNC_S"O$-=_P"1
MAU/_`*^Y?_0S7M]>(:[_`,C#J?\`U]R_^AFGEWQ2#-?@CZGM]!`(P1D&BJ5[
MJMGI]S:6]S*4ENGV0@*3N.0.W3[PKSTFW9'J2DHJ[.&TC0KS3?B"I^R3"T22
M4I,(SL"E&V_-C'<#Z\5/\3?^87_VU_\`9*[^H+BRM;S;]IMH9]N=OFQAL9ZX
MS74L4_:QJ26RL<;P:]C*E%[N_P"7^1G>%;,6/AFQCZL\8E8[<'+?-S],X_"N
M8^)O_,+_`.VO_LE=_P!*X#XF_P#,+_[:_P#LE&%ES8A2?6_Y,6-BH81Q72WY
MHW_!/_(H6/\`VT_]&-5+XA67VCP^MRH7=;2@DGKM;Y2!^)7\JN^"?^10L?\`
MMI_Z,:MV:&*XB:*:-)(VZHZ@@_@:B4^3$.79LTA353"J#ZI?D<I\.O\`D7)?
M^OEO_05IOQ'_`.1>M_\`K[7_`-`>NKM[:"UC,=O!'"A.=L:!1GUP*Y3XC_\`
M(O6__7VO_H#U=*?/B5+NR*\/9X1P[(/AQ_R+UQ_U]M_Z`E=A7'_#C_D7KC_K
M[;_T!*["L\5_&D:8/^!'T/'Q?+K_`(UMKJ6%52>XB#1-\PP-H(YZYQ^M>P5X
M<8[K0=9C\Z,)<VLB2%"<C/##.#]*]HL+^VU*SCNK6021..".WL?0UTXZ-E%Q
MVL<F73NYJ7Q7U*/B727UK1);.+R_.+*T;/T4@C)]N,C\:R_`%I<V>BW$=U;R
MP.;@L%E0J2-J\X-=717(JK5-T^AW.C%U55ZI6"BBBLC8****`"N(^(,\EP=-
MTF';NN)=^3D<_=7GT^8_D*[>O+]3U.:_\=FYAT^6\6P?:D,.<D(3\Q(!XW'/
M3T%=6$BW4YNQQ8Z:5/E?5V_S._T*P&F:'9V@`#)&"^#GYCRWZDUP'Q!TS[)J
MZ7_F;OMF?DVXV[%4?CG-=!_PE^L?]"G??F__`,;K"\5ZM?ZQIL8N/#US9K!(
M'\^0,0`1C&2HQDD=^PK;#PJQK<TNN^J.?%U*,Z')'IMH^GR[';^&+LWWAFPF
M((/E",Y.22IVD_CC/XUK5QGPYO?.TBYM&+$V\NX9/`5AP!^(8_C79UR5X<E2
M2.[#3YZ,9>1Q_P`1_P#D7K?_`*^U_P#0'KD_#_B;4='LGM;.VMY4:0R$R9SG
M`'J/05UGQ'_Y%ZW_`.OM?_0'H^''_(O7'_7VW_H"5V4Y*.%NU?4X9Q<L;9.V
MAS>K>,]9O+)[66*"W5\9>'<&X.>#NXZ5N_#7_D&WW_78?RKKK^PM]2LWM+I-
M\+XW#..AR/Y5C^$M`N=`M+B*YEBD:60,#&20!C'<"HE7IRH2BE9FRP]2.(C-
MNZL_D=#6;X@_Y%S4O^O:3_T$UI5F^(/^1<U+_KVD_P#037'#XD=E3X'Z'.^!
M;9+SP?>6LA(2:62-B.H!10?YUS.E`Z%X^CMT#,BW1@`+=58[03^8/X5UGPZ_
MY%R7_KY;_P!!6N=^(5@;778[Y-VVZ0$G/1UP#C\-OZUZ5.5Z\Z;V=SRJL;8:
MG56\;'I%]=?8M/N;LIO\B)I-N<9V@G&?PKC_`(=6WF6]_J<K;YI9?++,,MP-
MQ.?<L/RIWBW6TN?!=JR;/,U#9E%;.W&&;'T8!?QKI=!TS^Q]%MK(L&>-278=
MV))/ZG%<MO9T6GNW^7_!.R_M<0FMHJ_S?_`/,?&W_(WWW_;/_P!%K7K]>0>-
MO^1OOO\`MG_Z+6O7ZTQ?\*GZ?Y&.!_C5O7]6%>(:[_R,.I_]?<O_`*&:]OKQ
M#7?^1AU/_K[E_P#0S5Y=\4B,U^"/J=2?'>N`$FQL\#_>_P#BJR4UV[U[Q7I,
M]V(U,=Q$BI&"%'S@YP2>?\!7KE<]K?AV34M=TO4H&B1K:13-O)RRJP8`8'7[
MWYU%+$4KOW;>9KB,-5:7+-O5::?\`Z&BBBN$]`*X#XF_\PO_`+:_^R5W]<!\
M3?\`F%_]M?\`V2NK!_QX_/\`(X\P_P!WE\OS1O\`@G_D4+'_`+:?^C&KH*Y_
MP3_R*%C_`-M/_1C5T%95_P"++U9MA_X,/1?D%<?\1_\`D7K?_K[7_P!`>NPK
MC_B/_P`B];_]?:_^@/58;^-$C&?P)>@?#C_D7KC_`*^V_P#0$KL*X_X<?\B]
M<?\`7VW_`*`E=A1BOXT@P?\``CZ'->*/"<6O!;B!UAO4&T,WW7'HW^/^1YG#
M<7^A:DXBE>"YA<HX5N,@\@XX(R*]QJAJ>C6&KPO'=VZ,S+M$H4;U'48;J*UH
M8OD7)-71CB<$JDO:4W:1A^&O&D>M7"V5S!Y-VRDJ4Y1\<GW''UZ=:ZNO&_$O
MAR7P]>(AD\VWE!,4F,'CJ"/49'^>*[WP1K<FK:0T5RY>YM6",[')93]TD^O!
M'X>]5B,/%1]K2V)PF)FYNC6^)'3T445PGHA1110!5U&]33M-N;Q]I$,;/@MC
M<0.!GW.!^-<7\-;0A+^\9!@E8D?OQDL/U6JWCW7_`#[@:7:R@PHO[\HV0S9!
M"GZ8_7VK0^'%Y;C2[BS,J"X\\R",G!*E5&1Z]#7>J4H89OO;[CS76C4QD8K[
M-_O.WK/URQ.I:)>6B@%Y(SLSTW#D?J!6A4-U=VUE"9KJ>.&,?Q.P`KABVFFM
MST)I.+4MCS#P%J,5CKKQS2%4N(Q&H[,Y9=O\S7JM>`JS(P9258'((."#7N&D
M:E%JVF07<;QEG13(J-G8V.5/TKT,?2M)374\S*ZUXNF^ASOQ'_Y%ZW_Z^U_]
M`>CX<?\`(O7'_7VW_H"57^(M];-IEO9K/&UP)Q(8U;)4!3R1V^\*A\"ZUING
M:)-#>7D4,AN68*YY(VJ,_H:2C)X2R74;G%8Z[?0[ZLW7M730])DO6C$A5E58
MR^W>2>F<'MD_A47_``E.A_\`03M_^^JX/QMXCCU>XCL[1P]I"=V]2?WC8]".
MW(_&L*&'E.HE):'3B<5"G2;C)7Z'H>C:B^JZ<EV]OY&_!"[]W!`.<X'K3?$'
M_(N:E_U[2?\`H)I=!`'A[3<`#-K$?_'!67XRUBUL]$N[3[1']KFCVK%G+8)`
M)XZ<$]?2HC&]6T5U-)3M1YI/I^A6^'7_`"+DO_7RW_H*U-X_M#<^&&D4X^SR
MK*1C.1RN/_'L_A5+X=7EO_9,UH9HQ<>>SB(M\Q7:O('?H:Z^[MDO+.>UD+".
M:-HV*]<$8./SK6K)T\0Y>9C1BJN%4>ZL>0^&(9]1\0Z;;&5S%!+YH4Y94"_,
M<#MDC'XU[)6'HGA2PT&ZDN+62X>1TV$RL#@9!XP!Z"MJ22.&-I)75$49+,<`
M#ZTL5656?N[#P5"5&FU/=GD7C;_D;[[_`+9_^BUKU^O%_%%['J'B6^N(BIC+
MA596R&"@+D'WQFO6]+U2VU:S%Q;2HXR0RJV2ISW[BML7%^RI^2_R.?`R3K5=
M=W^K+M>(:[_R,.I_]?<O_H9KVN:>&VB:6>5(HUZN[!0/Q->&:A<B]U*ZN@NT
M3S/)MSG&XDX_6GER?-)DYJURQ1[O161_PE.A_P#03M_^^JI:KXSTRSTZ66SN
MH;FX`Q'&">3ZGCH*XU1J-VY6>BZ])*[DAR>*DD\6G0DM@P!*_:!+W";B-N/4
M$=:Z*O(_!\SW'C:UFE8M)(TKLQ[DHQ)KURM,52C2DHKL88*O*M"4I=W]P5P'
MQ-_YA?\`VU_]DKOR0!DG`%>9?$+5+:^O+*"UEBF6%&8R12!AEB!CCH1M_6JP
M2;K)_P!;"S"26'DGY?F=;X)_Y%"Q_P"VG_HQJZ"N.\!:Q:OHD>GRSPQW$4C*
MD;/AG!.[(!Z\DCCTKL:RQ$6JLK]S7"R4J,;=D%<?\1_^1>M_^OM?_0'KL*X7
MXBZA:R:=!91SQ/.MQO=%<$IA2.1V^]WJL*FZT;$XUI4)7+7PX_Y%ZX_Z^V_]
M`2NKNKA+2TFN9`Q2)&D8+U(`SQ7#_#S5+:&QNK*>:&)_.#IOD"E]PQ@`]<;1
M^==?K7_("U#_`*]I/_033Q,?W[3[BPDE]7BUV*VA^(K/Q`D[6B3(82`PE4`\
MYQT)]#6O7B_AO6FT+5TN=H:)U\N52<?*2.?P(!KU==?T=E##5;+!&>9U!_+-
M5B<,Z<_=6A&$Q:JP]]ZHP/B/_P`B];_]?:_^@/5#X9=-4/\`UR_]GK,\9:\=
M<ODL+(&2W@8D&,EO-;'7&.W/YFNT\(:2=(T"))%=9YCYTJN,%20./P`'7OGZ
M5M/]WA>66[,(6JXWGCLC>HHHKSCU0HHHH`R_^$;T7_H%VO\`W[%/BT#2()DE
MBTZV21"&5EC&01WK1HJN>7<CV<.R"JMYIMEJ&S[9:Q3[,[?,7.,]<?D*M44D
MVM44TFK,R_\`A&]%_P"@7:_]^Q5JSTVRT_?]CM8H-^-WEKC..F?S-6J*;E)Z
M-B4(IW2,P^'-&8Y.F6I/_7,4G_"-Z+_T"[7_`+]BM2BCGEW%[.'9&7_PC>B_
M]`NU_P"_8H_X1O1?^@7:_P#?L5J44<\NX>SAV0R*)(8DBB0)&BA54#``'053
MN=$TN\G:>XL+>65L;G=`2<#'\JOT4DVM44XIJS1GP:%I5M,DT&GV\<J'*NJ`
M$&M"BBAMO<%%+9!5>[L;6_B$5W;QSQAMP61<@'U_4U8HI)VV!I/1F7_PC>B_
M]`NU_P"_8JU9Z98Z>7-G:0P%\;O+4#..E6J*ISD]&Q*$4[I$%W96U_"(KN".
M:,'<%=<C/K5+_A&]%_Z!=K_W[%:E%"E);,'"+U:,O_A&]%_Z!=K_`-^Q1_PC
M>B_]`NU_[]BM2BCGEW%[.'9%"VT32[.=9[:PMXI5SM=$`(R,5?HHI-M[E**C
MLADL231/%*@>-U*LI&00>HK._P"$;T7_`*!=K_W[%:E%"DULQ.,9;HS%\.Z,
MC!ETRU#`Y!$8X-:=%%#;>XU%1V05FR>'M'ED:1]-M6=B68F,9)-:5%";6P.*
MENC+_P"$;T7_`*!=K_W[%:E%%#DWNQ*,8[(S[C0M)NPWG:=:L6ZMY0#?F.:H
M?\(5X>SG^S__`"-)_P#%5OT5:JS6TG]Y,J-.6\4_D4[+2=/T[FSLX86V[2R(
M-Q'H3U-7***AMMW9:22L@HHHI#"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
0*`"BBB@`HHHH`****`/_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
